Best practice in treating infants and children with proven, probable or suspected invasive fungal infections

Current Opinion in Infectious Diseases

Volumn 24, Issue 3, 2011, Pages 225-229

  Katragkou, Aspasia ^a   Roilides, Emmanuel ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

antifungal agents; Aspergillus; Candida; mycoses; paediatric

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; DEFERASIROX; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE;

ARTICLE; ASPERGILLOSIS; CANDIDEMIA; CHILD; CHILL; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFANT; INVASIVE ASPERGILLOSIS; LOADING DRUG DOSE; MUCORMYCOSIS; NEPHROTOXICITY; NONHUMAN; PRACTICE GUIDELINE; RECOMMENDED DRUG DOSE; SYSTEMIC MYCOSIS;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; CHILD; ECHINOCANDINS; FEVER OF UNKNOWN ORIGIN; HUMANS; INFANT; MYCOSES; PYRIMIDINES; TRIAZOLES;

EID: 79955521447     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3283460e22     Document Type: Article

References (43)

1. Horn DL, Neofytos D, Anaissie EJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009; 48:1695-1703.
2. Zaoutis TE, Prasad PA, Localio AR, et al. Risk factors and predictors for candidemia in pediatric intensive care unit patients: implications for prevention. Clin Infect Dis 2010; 51:e38-e45.
3. Blyth CC, Chen SC, Slavin MA, et al. Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. Pediatrics 2009; 123:1360-1368.
4. Lass-Florl C. The changing face of epidemiology of invasive fungal disease in Europe. Mycoses 2009; 52:197-205.
5. Groll AH, McNeil Grist L. Current challenges in the diagnosis and management of invasive fungal infections: report from the 15th International Symposium on Infections in the Immunocompromised Host; Thessaloniki, Greece, 22-25 June 2008. Int J Antimicrob Agents 2009; 33:101-104.
6. Steinbach WJ. Invasive aspergillosis in pediatric patients. Curr Med Res Opin 2010; 26:1779-1787.
7. Zaoutis T. Candidemia in children. Curr Med Res Opin 2010; 26:1761-1768.
8. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813-1821.
9. Steinbach WJ. Epidemiology of invasive fungal infections in neonates and children. Clin Microbiol Infect 2010; 16:1321-1327.
10. Arendrup MC, Fisher BT, Zaoutis TE. Invasive fungal infections in the paediatric and neonatal population: diagnostics and management issues. Clin Microbiol Infect 2009; 15:613-624.
11. Groll AH, Tragiannidis A. Update on antifungal agents for paediatric patients. Clin Microbiol Infect 2010; 16:1343-1353.
12. Mondal RK, Singhi SC, Chakrabarti A, Jayashree M. Randomized comparison between fluconazole and itraconazole for the treatment of candidemia in a pediatric intensive care unit: a preliminary study. Pediatr Crit Care Med 2004; 5:561-565.
13. Queiroz-Telles F, Berezin E, Leverger G, et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J 2008; 27:820-826.
14. Blyth CC, Hale K, Palasanthiran P, et al. Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections. Cochrane Database Syst Rev 2010:CD006343.
15. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503-535.
16. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:327-360. (Pubitemid 351265310)
17. Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in nonneutropenic patients: a randomised noninferiority trial. Lancet 2005; 366:1435-1442. (Pubitemid 41483809)
18. Segal BH. Aspergillosis. N Engl J Med 2009; 360:1870-1884.
19. Zaoutis T, Lehrnbecher T, Groll AH, et al. Safety experience with caspofungin in pediatric patients. Pediatr Infect Dis J 2009; 28:1132-1135.
20. Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002; 21:240-248. (Pubitemid 34214142)
21. Cesaro S, Strugo L, Alaggio R, et al. Voriconazole for invasive aspergillosis in oncohematological patients: a single-center pediatric experience. Support Care Cancer 2003; 11:722-727. (Pubitemid 37432629)
22. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-415. (Pubitemid 34851833)
23. Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35:359-366. (Pubitemid 34852563)
24. Ellis M, Spence D, de Pauw B, et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 1998; 27:1406-1412. (Pubitemid 29242412)
25. Burgos A, Zaoutis TE, Dvorak CC, et al. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics 2008; 121:e1286-e1294.
26. Maertens JA, Madero L, Reilly AF, et al. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J 2010; 29:415-420.
27. Goldberg E, Gafter-Gvili A, Robenshtok E, et al. Empirical antifungal therapy for patients with neutropenia and persistent fever: systematic review and meta-analysis. Eur J Cancer 2008; 44:2192-2203.
28. Maertens J, Groll AH, Cordonnier C, et al. Treatment and timing in invasive mould disease. J Antimicrob Chemother 2011; 66 (Suppl 1):i37-i43.
29. Thomas L, Baggen L, Chisholm J, Sharland M. Diagnosis and treatment of aspergillosis in children. Expert Rev Anti Infect Ther 2009; 7:461-472.
30. Steinbach WJ, Addison RM, McLaughlin L, et al. Prospective Aspergillus galactomannan antigen testing in pediatric hematopoietic stem cell transplant recipients. Pediatr Infect Dis J 2007; 26:558-564. (Pubitemid 47014154)
31. Hayden R, Pounds S, Knapp K, et al. Galactomannan antigenemia in pediatric oncology patients with invasive aspergillosis. Pediatr Infect Dis J 2008; 27:815-819.
32. Desai R, Ross LA, Hoffman JA. The role of bronchoalveolar lavage galactomannan in the diagnosis of pediatric invasive aspergillosis. Pediatr Infect Dis J 2009; 28:283-286.
33. Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 2004; 48:2166-2172. (Pubitemid 38691615)
34. Walsh TJ, Driscoll T, Milligan PA, et al. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob Agents Chemother 2010; 54:4116-4123.
35. Goutelle S, Larcher R, Padoin C, et al. Oral voriconazole dose in children: one size does not fit all. Clin Infect Dis 2010; 51:870-871.
36. Neely M, Jafri HS, Seibel N, et al. Pharmacokinetics and safety of caspofungin in older infants and toddlers. Antimicrob Agents Chemother 2009; 53:1450-1456.
37. Lehrnbecher T, Attarbaschi A, Duerken M, et al. Posaconazole salvage treatment in paediatric patients: a multicentre survey. Eur J Clin Microbiol Infect Dis 2010; 29:1043-1045.
38. Campo M, Lewis RE, Kontoyiannis DP. Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998-2009. J Infect 2010; 60:331-337.
39. Ruping MJ, Heinz WJ, Kindo AJ, et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother 2010; 65:296-302.
40. Skiada A, Pagano L, Groll A, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect 2011 [Epub ahead of print].
41. Cortez KJ, Roilides E, Quiroz-Telles F, et al. Infections caused by Scedosporium spp. Clin Microbiol Rev 2008; 21:157-197.
42. Roilides E, Zaoutis TE, Walsh TJ. Invasive zygomycosis in neonates and children. Clin Microbiol Infect 2009; 15 (Suppl 5):50-54.
43. Cornely OA. Current controversies in treating invasive zygomycosis. J Pediatr Hematol Oncol 2010; 32:83-84.